Xenitra Limited (ASX: XEN) has undergone a major transformation, shifting from a tourism-dependent retail model into a broader platform focused on nutritionals, OTC medicines, and digital commerce through OPAL.
In this video, we explore:
How Xenitra rebuilt revenue from A$2.7 million in FY23 to A$39.8 million in FY25
The company’s new growth pillars across Greater China markets
Key commercial agreements with Rockcheck-Danone, Kangsheng, EZZ Life Science and other partners
The potential role of its OPAL digital-commerce ecosystem
The path toward improving margins, positive EBITDA and sustainable cash flow
Key risks including execution challenges, regulation, dilution and market exposure
Watch the full analysis to understand the company’s strategy, financial outlook, valuation assumptions and the milestones investors are watching.
Read the full Xenitra research report from Proactive Equities by clicking here.
Browse Videos by Popular Categories
For exclusive, in-depth research, timely high-conviction investment ideas, and actionable trade signals designed to help you stay ahead, join Proactive Equities today.
Open a Free Basic Account